SureGene
SureGene, PGXL Partner on PGx Test for Antipsychotic Drugs
This article has been updated to include information about a competing product in the market.
The pharmacy benefits manager will study whether its members are more willing to take -- and stick with -- antidepressant and antipsychotic drugs prescribed to them based on a genetic test that suggests they are most likely to benefit from such treatment.
The company has received a $224,500 Therapeutic Discovery Project Tax Credit and a $365,579 SBIR Phase II matching grant from the Commonwealth of Kentucky to continue the development of a predictive test to guide treatment of antipsychotic drugs.
Medco, SureGene to Validate SULT4A1 Variants for Gauging Patient Response to Antipsychotic Drugs
Premium
The alliance aims to validate whether polymorphisms identified by SureGene in the SULT4A1 gene can be used to stratify best responders to the four most widely prescribed atypical antipsychotics.
SureGene, Medco Research Partner on PGx Study for Antipsychotic Drugs
The two firms will study whether genetic variations can help predict response to widely prescribed antipsychotic drugs.